Neuromod Publishes Results of Second Large Scale Clinical Trial for Tinnitus in Top-Tier Scientific Journal, Shows Greater Improvement of Symptoms

Dublin (ots/PRNewswire) - - Second large-scale trial shows greater reduction in
tinnitus symptom severity using bimodal neuromodulation device, Lenire®

- 91% of treatment compliant participants experienced improvement in tinnitus
symptoms that sustained 12 months after treatment

- 87.8% said they would recommend treatment to others with tinnitus

Neuromod Devices Limited, the Irish medical device company specialising in the
treatment of tinnitus, has published the results of the company's TENT-A2
(Treatment Evaluation of Neuromodulation for Tinnitus - Stage A2) clinical trial
in the highly regarded scientific journal, Nature - Scientific Reports in a
paper titled: "Different bimodal neuromodulation settings reduce tinnitus
symptoms in a large randomized trial."

The full paper is available here: TENT-A2 results
(https://www.neuromoddevices.com/tenta2) [1].

Tinnitus, commonly referred to as "ringing in the ears" is thought to affect
between 10 - 15% of the global adult population[2,3]. The TENT-A2 trial, which
included 191 participants, is the company's second large-scale clinical trial
and sought to replicate and further enhance the results demonstrated in the
company's TENT-A1 trial, a study that evaluated the safety and efficacy of
Lenire®, the company's non-invasive bimodal neuromodulation device in 326
participants.

The publication of the TENT-A2 results in Nature - Scientific Reports follows on
from the publication of the TENT-A1 results as the cover story in Science -
Translational Medicine in 2020 (the full TENT-A1 results paper is available
here: TENT-A1 results (https://www.neuromoddevices.com/tenta1results) )[4]. This
second major publication continues Neuromod's strategy to establish the clinical
credibility of bimodal neuromodulation through publishing large-scale clinical
trials in top-tier peer-reviewed journals.

The TENT-A2 study investigated if changing treatment stimuli after six weeks of
treatment would result in greater improvement in tinnitus symptoms than observed
in the TENT-A1 study, during which participants were treated with the same
stimuli for the entire 12-week treatment period.

In the TENT-A1 study, treatment compliant participants demonstrated a mean
improvement that was more than twice the published clinically important
improvement. In the TENT-A2 study, 95% of treatment compliant participants
achieved a greater average improvement in symptoms compared to TENT-A1[1,4,5]
and almost three times the published clinically important improvement. 91% of
treatment compliant participants achieved an improvement that sustained 12
months after treatment concluded[1,5].